

Kinrix™

Vaccine	Recommended Age	Booster Schedule
Kinrix™ (DTaP-IPV) <i>(GlaxoSmithKline)</i>	4 – 6 years (Not approved for the primary series of DTaP and/or IPV)	0.5 mL at least 6 months after the 4 th dose of DTaP and 6 months after the previous dose of IPV



Kinrix™ Vaccine Recommendations

General Recommendations:

- Kinrix™ is not approved for the primary series of DTaP and/or IPV.
- A single dose of Kinrix™ is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the DTaP vaccine series.
- For use in children aged 4-6 years of age who previously received INFANRIX (DTaP) and/or PEDIARIX (DTaP-Hep B-IPV) for the first three doses and INFANRIX (DTaP) for the fourth dose.
- A single dose of Kinrix™ is indicated for immunization against poliovirus as the fourth dose in the IPV vaccine series.
- **DTaP:** a fifth dose of DTaP-containing vaccine is not needed if the fourth dose was given on or after the fourth birthday.
- **IPV:** A fourth dose of IPV-containing vaccine is not needed if the third IPV dose was given on or after the fourth birthday and was given at least 6 months after the previous dose.
- Kinrix™ may be used when any component of the combination is indicated, and if the other components are not contraindicated for the booster dose at 4-6 years of age.

Administration:

- Whenever possible, it is recommended that the same DTaP vaccine should be used for all doses in the series.
- If a provider does not know or have available the DTaP vaccine product previously administered, vaccine administration should not be deferred and Kinrix™ may be administered.

Vaccine Storage and Handling:

- Kinrix™ should be stored between 35° and 46°F. Aim for 40°F.
- Do not allow vaccine to freeze – discard if frozen.

Adverse Reactions

- Injection site: pain, redness, swelling, increase in arm circumference.
- Systemic: drowsiness, fever, loss of appetite.

Contraindications

- Hypersensitivity (anaphylaxis reaction after a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis or poliovirus-containing vaccine).
- Encephalopathy (coma, decreased level of consciousness, prolonged seizures).
- Progressive neurologic disorder (infantile spasms, uncontrolled epilepsy, progressive encephalopathy).

Precautions

- Guillain-Barre Syndrome occurring within 6 weeks of receipt of a prior vaccine containing tetanus toxoid.
- Adverse events following prior pertussis vaccination.
- Children at risk for seizures.
- Temperature of 105° within 48 hours not due to another identifiable cause.
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours.
- Seizures with or without fever occurring within 3 days.